Wave Life Sciences [WVE] vs Regeneron [REGN] Detailed Stock Comparison

Wave Life Sciences Ltd.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Wave Life Sciences Ltd. wins in 3 metrics, Regeneron Pharmaceuticals, Inc. wins in 15 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Wave Life Sciences Ltd. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) -5.93 18.00 Regeneron Pharmaceuticals, Inc.
Price-to-Book Ratio 2.60 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 3.38 9.51 Wave Life Sciences Ltd.
PEG Ratio 0.02 -4.80 Wave Life Sciences Ltd.
EV/EBITDA -3.66 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 0.00% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) -327.44% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -54.97% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -27.18% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-188.21M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 9.48% 25.39% Regeneron Pharmaceuticals, Inc.
Price-to-Sales Ratio (TTM) 31.64 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $775.24M $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 18.14 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) $0 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-1.19 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) -1.32 0.40 Wave Life Sciences Ltd.
Short % of Float 9.00% 2.55% Regeneron Pharmaceuticals, Inc.

Wave Life Sciences Ltd. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

WVE
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Wave Life Sciences Ltd.1.23%-10.82%-23.83%-58.92%-18.60%-64.33%
Regeneron Pharmaceuticals, Inc.2.66%-5.03%-15.02%-23.79%-18.77%-22.36%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Wave Life Sciences Ltd.9.48%44.62%-2.81%-58.62%-58.62%-58.62%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: Wave Life Sciences Ltd. vs Regeneron Pharmaceuticals, Inc.

MetricWVEREGN
Market Information
Market Cap i$1.35B$80.98B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i3,826,936642,495
90 Day Avg. Volume i5,712,955617,765
Last Close$5.76$618.95
52 Week Range$5.02 - $21.73$476.49 - $821.11
% from 52W High-73.49%-24.62%
All-Time High$56.00 (Sep 24, 2018)$1,211.20 (Aug 26, 2024)
% from All-Time High-89.71%-48.90%
Growth Metrics
Quarterly Revenue Growth-0.79%0.03%
Quarterly Earnings GrowthN/A-0.08%
Financial Health
Profit Margin (TTM) i0.00%0.31%
Operating Margin (TTM) i-3.27%0.23%
Return on Equity (TTM) i-0.55%0.15%
Debt to Equity (MRQ) i3.389.51
Cash & Liquidity
Book Value per Share (MRQ)$2.76$304.65
Cash per Share (MRQ)$3.20$83.86
Operating Cash Flow (TTM) i$-187,492,992$4.98B
Levered Free Cash Flow (TTM) i$-112,548,376$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Wave Life Sciences Ltd. vs Regeneron Pharmaceuticals, Inc.

MetricWVE (Apr 26, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-5.9318.00
Forward P/E i-5.3614.21
PEG Ratio i0.02-4.80
Price to Sales (TTM) i31.645.50
Price to Book (MRQ) i2.602.45
Market Capitalization
Market Capitalization i$1.35B$80.98B
Enterprise Value i$775.24M$70.98B
Enterprise Value Metrics
Enterprise to Revenue i18.144.95
Enterprise to EBITDA i-3.6616.72
Risk & Other Metrics
Beta i-1.320.40
Book Value per Share (MRQ) i$2.76$304.65

Financial Statements Comparison: Wave Life Sciences Ltd. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricWVE (2025)REGN (2025)
Revenue/Sales i42.73M14.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i0.0%14.6%
Gross Profit iN/A12.24B
Gross Margin i0.0%85.4%
Research & Development i182.78M5.85B
Operating Income (EBIT) i-215.38M3.70B
Operating Margin i-504.1%25.8%
EBITDA i-217.01M5.00B
EBITDA Margin i-507.9%34.8%
Pre-Tax Income i-204.38M5.23B
Pre-Tax Income % of Revenue i-478.3%36.5%
Income Tax i0725.80M
Income Tax % of Revenue i0.0%5.1%
Net Income (Profit) i-204.38M4.50B
Profit Margin i-478.3%31.4%

Balance Sheet & Liquidity Metrics

MetricWVE (2025)REGN (2025)
Cash & Equivalents i602.07M3.12B
Total Current Assets i614.81M18.02B
Total Current Assets % of Revenue i1,438.9%125.7%
Total Current Liabilities i95.07M4.37B
Total Current Liabilities % of Revenue i222.5%30.5%
Long-Term Debt i9.41M2.71B
Long-Term Debt % of Revenue i22.0%18.9%
Total Shareholders Equity i518.36M31.26B
Retained Earnings i-1.33B35.80B
Retained Earnings % of Revenue i-3,104.0%249.6%
Property, Plant & Equipment i12.46M1.54B

Cash Flow Statement Comparison

MetricWVE (2025)REGN (2025)
Operating Cash Flow i-194.13M6.30B
Operating Cash Flow % of Revenue i-454.3%43.9%
Capital Expenditures i-718,0000
Free Cash Flow i-188.21M3.77B
FCF Margin i-440.5%26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricWVEREGN
Shares Short i13.21M2.55M
Short Ratio i2.244.46
Short % of Float i9.00%2.55%
Shares Outstanding i187.66M105.72M
Float Shares i124.17M98.55M
% Held by Insiders i14.21%1.98%
% Held by Institutions i93.84%91.08%
% Held by Public i-8.05%6.94%

Dividend Analysis & Yield Comparison: Wave Life Sciences Ltd. vs Regeneron Pharmaceuticals, Inc.

MetricWVEREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026